Sangamo (NASDAQ: SGMO) awards 225,000 stock options to accounting chief

Q: How many stock options did SGMO grant to Principal Accounting Officer Nikunj Jain?

Sangamo Therapeutics granted 225,000 stock options to Principal Accounting Officer Nikunj Jain. These options are exercisable for an equal number of common shares and increase his potential equity exposure to the company through a long-dated, service-based compensation award.

Q: What is the exercise price and expiration date of Nikunj Jain’s SGMO stock options?

The granted options have an exercise price of $0.2601 per share and expire on March 31, 2036 . This fixed exercise price and long expiration provide a multi-year incentive window tied to Sangamo Therapeutics’ future common stock performance.

Q: Did the SGMO Form 4 show Nikunj Jain buying or selling common shares on the market?

The Form 4 reports a grant of stock options , not an open-market trade. No purchases or sales of SGMO common stock were disclosed; instead, Mr. Jain received options as a compensation-related award, which may be exercised in the future if vested.

Q: What is Nikunj Jain’s option position in SGMO after this reported grant?

After this grant, Mr. Jain holds 225,000 stock options directly, according to the filing’s post-transaction totals. These options relate to Sangamo Therapeutics common stock and reflect his potential, rather than current, share ownership stake at this stage.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sangamo Therapeutics Principal Accounting Officer Nikunj Jain received a grant of stock options as equity compensation. The award covers 225,000 options to buy common stock at an exercise price of $0.2601 per share, expiring on March 31, 2036.

One quarter of the options vest on the first anniversary of the grant date, and the remaining options vest in 24 equal monthly installments, subject to Mr. Jain’s continuous service and the terms of the company’s 2018 equity incentive plan. No open‑market share purchases or sales were reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jain Nikunj

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	225,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 225,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 225,000 options Exercise price: $0.2601 per share Expiration date: March 31, 2036 +3 more

6 metrics

Stock options granted 225,000 options Grant to Principal Accounting Officer on April 1, 2026

Exercise price $0.2601 per share Strike price for granted stock options

Expiration date March 31, 2036 Option term end date

Post-grant option holdings 225,000 options Total derivative securities following transaction

Initial vesting 25% after 1 year One quarter vests on first anniversary of grant

Remaining vesting schedule 24 monthly installments Balance vests over 24 successive months

Key Terms

Stock Option (Right to Buy), Continuous Service, 2018 EIP, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Continuous Service financial

"subject to the Reporting Person's Continuous Service"

2018 EIP financial

"as provided in the 2018 EIP"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Nikunj

(Last)

(First)

(Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BOULEVARD

(Street)

RICHMOND

CALIFORNIA

94804

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.2601	04/01/2026		A		225,000		⁽¹⁾	03/31/2036	Common Stock	225,000	$0	225,000	D

Explanation of Responses:

1. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

	/s/ Scott Willoughby, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sangamo Therapeutics (SGMO) report for Nikunj Jain?

Sangamo Therapeutics reported that Principal Accounting Officer Nikunj Jain received a grant of 225,000 stock options. These options give him the right to buy common shares at a fixed price as part of his equity compensation package, rather than representing a market purchase or sale.

How many stock options did SGMO grant to Principal Accounting Officer Nikunj Jain?

Sangamo Therapeutics granted 225,000 stock options to Principal Accounting Officer Nikunj Jain. These options are exercisable for an equal number of common shares and increase his potential equity exposure to the company through a long-dated, service-based compensation award.

What is the exercise price and expiration date of Nikunj Jain’s SGMO stock options?

The granted options have an exercise price of $0.2601 per share and expire on March 31, 2036. This fixed exercise price and long expiration provide a multi-year incentive window tied to Sangamo Therapeutics’ future common stock performance.

How do the Sangamo Therapeutics options granted to Nikunj Jain vest over time?

One quarter of the options vest and become exercisable on the first anniversary of the grant date. The remaining three quarters vest in 24 equal monthly installments, contingent on Mr. Jain’s continuous service under the company’s 2018 equity incentive plan.

Did the SGMO Form 4 show Nikunj Jain buying or selling common shares on the market?

The Form 4 reports a grant of stock options, not an open-market trade. No purchases or sales of SGMO common stock were disclosed; instead, Mr. Jain received options as a compensation-related award, which may be exercised in the future if vested.

What is Nikunj Jain’s option position in SGMO after this reported grant?

After this grant, Mr. Jain holds 225,000 stock options directly, according to the filing’s post-transaction totals. These options relate to Sangamo Therapeutics common stock and reflect his potential, rather than current, share ownership stake at this stage.